Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics

Checkpoint Therapeutics, Inc. (CKPT): $2.04

0.03 (-1.45%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

CKPT Price/Volume Stats

Current price $2.04 52-week high $3.91
Prev. close $2.07 52-week low $1.30
Day low $2.00 Volume 251,900
Day high $2.10 Avg. volume 592,998
50-day MA $1.97 Dividend yield N/A
200-day MA $2.18 Market Cap 47.99M

CKPT Stock Price Chart Interactive Chart >

CKPT POWR Grades

  • Growth is the dimension where CKPT ranks best; there it ranks ahead of 71.51% of US stocks.
  • CKPT's strongest trending metric is Quality; it's been moving down over the last 26 weeks.
  • CKPT ranks lowest in Stability; there it ranks in the 1st percentile.

CKPT Stock Summary

  • Of note is the ratio of CHECKPOINT THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 5.34% of US stocks have a lower such ratio.
  • For CKPT, its debt to operating expenses ratio is greater than that reported by just 0.22% of US equities we're observing.
  • CKPT's price/sales ratio is 308.18; that's higher than the P/S ratio of 98.78% of US stocks.
  • If you're looking for stocks that are quantitatively similar to CHECKPOINT THERAPEUTICS INC, a group of peers worth examining would be XBIT, RVMD, STTK, IMMP, and ARAV.
  • Visit CKPT's SEC page to see the company's official filings. To visit the company's web site, go to www.checkpointtx.com.

CKPT Valuation Summary

  • In comparison to the median Healthcare stock, CKPT's price/sales ratio is 14227.27% higher, now standing at 315.2.
  • CKPT's price/sales ratio has moved up 217.1 over the prior 79 months.

Below are key valuation metrics over time for CKPT.

Stock Date P/S P/B P/E EV/EBIT
CKPT 2023-12-29 315.2 -2.8 -1.0 -1.0
CKPT 2023-12-28 311.1 -2.8 -1.0 -1.0
CKPT 2023-12-27 300.0 -2.7 -1.0 -0.9
CKPT 2023-12-26 286.0 -2.6 -0.9 -0.9
CKPT 2023-12-22 257.3 -2.3 -0.8 -0.8
CKPT 2023-12-21 253.2 -2.3 -0.8 -0.8

CKPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CKPT has a Quality Grade of D, ranking ahead of 20.58% of graded US stocks.
  • CKPT's asset turnover comes in at 0.005 -- ranking 410th of 682 Pharmaceutical Products stocks.
  • VBIV, COLL, and ARWR are the stocks whose asset turnover ratios are most correlated with CKPT.

The table below shows CKPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.005 1 4.869
2021-03-31 0.004 1 4.383
2020-12-31 0.033 1 3.944
2020-09-30 0.037 1 3.435
2020-06-30 0.061 1 3.348
2020-03-31 0.117 1 3.498

CKPT Price Target

For more insight on analysts targets of CKPT, see our CKPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.80 Average Broker Recommendation 1.4 (Strong Buy)

Checkpoint Therapeutics, Inc. (CKPT) Company Bio


Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.


CKPT Latest News Stream


Event/Time News Detail
Loading, please wait...

CKPT Latest Social Stream


Loading social stream, please wait...

View Full CKPT Social Stream

Latest CKPT News From Around the Web

Below are the latest news stories about CHECKPOINT THERAPEUTICS INC that investors may wish to consider to help them evaluate CKPT as an investment opportunity.

Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit Outlook

We feel now is a pretty good time to analyse Checkpoint Therapeutics, Inc.'s ( NASDAQ:CKPT ) business as it appears the...

Yahoo | December 19, 2023

UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy

Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer. Checkpoint said the FDA did not state any concerns about the data or safety on the drug in its so-called complete response letter.

Yahoo | December 18, 2023

U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimabWALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the cosibelimab biologic license application (“BLA”) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma

Yahoo | December 18, 2023

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023

Some of the most explosive opportunities can be found in biotech stocks.

Ian Cooper on InvestorPlace | December 11, 2023

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a new patent (U.S. Patent No. 11,834,505) covering a method of treating various cancers, including cutaneous squamous cell carcinoma (“cSCC

Yahoo | December 5, 2023

Read More 'CKPT' Stories Here

CKPT Price Returns

1-mo -4.67%
3-mo -10.92%
6-mo 20.00%
1-year -41.55%
3-year -93.31%
5-year -92.87%
YTD -10.92%
2023 -55.19%
2022 -83.57%
2021 17.36%
2020 54.07%
2019 -5.49%

Continue Researching CKPT

Here are a few links from around the web to help you further your research on Checkpoint Therapeutics Inc's stock as an investment opportunity:

Checkpoint Therapeutics Inc (CKPT) Stock Price | Nasdaq
Checkpoint Therapeutics Inc (CKPT) Stock Quote, History and News - Yahoo Finance
Checkpoint Therapeutics Inc (CKPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!